Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: An in silico based mechanism

Breast Cancer Research

Volumn 13, Issue 3, 2011, Pages

  Fuentes, Gloria ^a   Scaltriti, Maurizio ^b,c   Baselga, José ^b,c   Verma, Chandra S ^a,d,e  

^a BIOINFORMATICS INSTITUTE   (Singapore)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; COMPUTER MODEL; DIMERIZATION; DRUG POTENTIATION; HUMAN; MOLECULAR DYNAMICS; OLIGOMERIZATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; SIMULATION; THERMODYNAMICS; BREAST TUMOR; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECT; FEMALE; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMPUTER SIMULATION; DRUG SYNERGISM; FEMALE; HUMANS; MOLECULAR DYNAMICS SIMULATION; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; THERMODYNAMICS;

EID: 84860390489     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2888     Document Type: Article

References (38)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073, 11252954.
2. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004, 44:195-217. 10.1146/annurev.pharmtox.44.101802.121440, 14744244.
3. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ. Structure of the extracellular region of Her2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-60. 10.1038/nature01392, 12610629.
4. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003, 11:495-505. 10.1016/S1097-2765(03)00048-0, 12620236.
5. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003, 284:31-53. 10.1016/S0014-4827(02)00098-8, 12648464.
6. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225. 10.1016/S0092-8674(00)00114-8, 11057895.
7. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712. 10.1126/science.2470152, 2470152.
8. Slamon DJ. Proto-oncogenes and human cancers. N Engl J Med 1987, 317:955-957. 10.1056/NEJM198710083171509, 3627214.
9. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475. 10.1038/nrc2656, 19536107.
10. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/Her2 action in breast cancer. Oncogene 2000, 19:6102-6114. 10.1038/sj.onc.1203973, 11156523.
11. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999, 26:60-70.
12. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010, 28:1138-1144. 10.1200/JCO.2009.24.2024, 20124182.
13. Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, Doern A, Snipas T, Perron K, Joseph I, Glaser SM, Ho SN, Reff ME, Hariharan K. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 2010, 9:2593-2604. 10.1158/1535-7163.MCT-09-1018, 20716637.
14. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5:317-328. 10.1016/S1535-6108(04)00083-2, 15093539.
15. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, Duke RE, Luo R, Merz KM, Pearlman DA, Crowley M, Walker RC, Zhang W, Wang B, Havik S, Riotberg A, Seabra G, Wong KF, Paesani F, Wu X, Brozell S, Tsui V, Gohlke H, Yang L, Tan C, Mongan J, Hornak V, Cui G, Beroza P, Mathews DH, Schafmeister C, et al. AMBER 9. 2006, University of California, San Francisco.
16. Wang J, Cieplak P, Kollman PA. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules?. J Comput Chem 2000, 21:1049-1074.
17. Dolinsky TJ, Nielsen JE, McCammon JA, Baker NA. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res 2004, 32:W665. 10.1093/nar/gkh381, 441519, 15215472.
18. Izaguirre JA, Catarello DP, Wozniak JM, Skeel RD. Langevin stabilization of molecular dynamics. J Chem Phys 2001, 114:2090.
19. Berendsen HJC, Postma JPM, Van Gunsteren WF, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys 1984, 81:3684.
20. Darden T, York D, Pedersen L. Particle mesh Ewald: An N log(N) method for Ewald sums in large systems. J Chem Phys 1993, 98:10089-10092.
21. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 1977, 22:327-341.
22. Grant BJ, Rodrigues APC, ElSawy KM, McCammon JA, Caves LSD. Bio 3 d: an R package for the comparative analysis of protein structures. Bioinformatics 2006, 22:2695. 10.1093/bioinformatics/btl461, 16940322.
23. Hayward S, Berendsen HJC. Systematic analysis of domain motions in proteins from conformational change: new results on citrate synthase and T4 lysozyme. Proteins 1998, 30:144-154. 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N, 9489922.
24. PyMOL. DeLano Scientific, Palo Alto, CA., http://www.pymol.org
25. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000, 33:889-897. 10.1021/ar000033j, 11123888.
26. Weiser J, Shenkin PS, Still WC. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). J Comput Chem 1999, 20:217-230.
27. Amadei A, Linssen AB, Berendsen HJ. Essential dynamics of proteins. Proteins 1993, 17:412-425. 10.1002/prot.340170408, 8108382.
28. Levy RM, Srinivasan AR, Olson WK, McCammon JA. Quasi-harmonic method for studying very low frequency modes in proteins. Biopolymers 1984, 23:1099-1112. 10.1002/bip.360230610, 6733249.
29. Stepanova M. Dynamics of essential collective motions in proteins: theory. Phys Rev E 2007, 76:51918.
30. Gohlke H, Kiel C, Case DA. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J Mol Biol 2003, 330:891-913. 10.1016/S0022-2836(03)00610-7, 12850155.
31. Balius TE, Rizzo RC. Quantitative Prediction of Fold Resistance for Inhibitors of EGFR. Biochemistry 2009, 48:8435-8448. 10.1021/bi900729a, 2741091, 19627157.
32. McGillick BE, Balius TE, Mukherjee S, Rizzo RC. Origins of Resistance to the HIVgp41 Viral Entry Inhibitor T20. Biochemistry 2010, 49:3575-3579. 10.1021/bi901915g, 2867330, 20230061.
33. Troise F, Cafaro V, Giancola C, D'Alessio G, De Lorenzo C. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor. FEBS J 2008, 275:4967-4979. 10.1111/j.1742-4658.2008.06625.x, 18795950.
34. Kästner J, Loeffler HH, Roberts SK, Martin-Fernandez ML, Winn MD. Ectodomain orientation, conformational plasticity and oligomerization of ErbB1 receptors investigated by molecular dynamics. J Struct Biol 2009, 167:117-128. 10.1016/j.jsb.2009.04.007, 19406245.
35. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010, 142:699-713. 10.1016/j.cell.2010.07.044, 20813259.
36. Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009, 28:461-468. 10.1038/onc.2008.394, 18978815.
37. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010, 122:35-43. 10.1007/s10549-009-0502-2, 19701706.
38. Thakur A, Lum LG. Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther 2010, 12:340-349.